DDInter1826 DDInter462
A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
Tolazamide {u} (Compound) upregulates {v} (Gene) TSC22D3
TSC22D3 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Tolazamide {u} (Compound) downregulates {v} (Gene) IER3
IER3 {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Tolazamide {u} (Compound) upregulates {v} (Gene) JADE2
JADE2 {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Tolazamide {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Dabrafenib
Tolazamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dabrafenib
Tolazamide {u} (Compound) upregulates {v} (Gene) TSC22D3
TSC22D3 {u} (Gene) is regulated by {v} (Gene) BRAF
BRAF {u} (Gene) is bound by {v} (Compound) Dabrafenib
Tolazamide {u} (Compound) downregulates {v} (Gene) IER3
IER3 {u} (Gene) is regulated by {v} (Gene) BRAF
BRAF {u} (Gene) is bound by {v} (Compound) Dabrafenib
Tolazamide {u} (Compound) downregulates {v} (Gene) PSMD2
PSMD2 {u} (Gene) regulates {v} (Gene) ERBB2
ERBB2 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Tolazamide {u} (Compound) upregulates {v} (Gene) JADE2
JADE2 {u} (Gene) regulates {v} (Gene) LIMK1
LIMK1 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Tolazamide {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dabrafenib
Tolazamide (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Dabrafenib (Compound)
Tolazamide (Compound) downregulates IER3 (Gene) and IER3 (Gene) is downregulated by Dabrafenib (Compound)
Tolazamide (Compound) upregulates JADE2 (Gene) and JADE2 (Gene) is downregulated by Dabrafenib (Compound)
Tolazamide (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Dabrafenib (Compound)
Tolazamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Tolazamide (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is regulated by BRAF (Gene) and BRAF (Gene) is bound by Dabrafenib (Compound)
Tolazamide (Compound) downregulates IER3 (Gene) and IER3 (Gene) is regulated by BRAF (Gene) and BRAF (Gene) is bound by Dabrafenib (Compound)
Tolazamide (Compound) downregulates PSMD2 (Gene) and PSMD2 (Gene) regulates ERBB2 (Gene) and ERBB2 (Gene) is upregulated by Dabrafenib (Compound)
Tolazamide (Compound) upregulates JADE2 (Gene) and JADE2 (Gene) regulates LIMK1 (Gene) and LIMK1 (Gene) is bound by Dabrafenib (Compound)
Tolazamide (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib